• Strata Critical forecasts fiscal 2026 revenue of $290 million and adjusted EBITDA of $34 million at guidance midpoints.
• Its preliminary 2027 outlook targets total growth above 30%, including acquisitions, with high-teens organic growth.
• Free cash flow conversion is projected at 60%-70% or higher, versus approximately 45%-63% expected for fiscal 2026.
• The outlook follows approximately 18% pro forma revenue growth in the first nine months of 2026.
• Third-quarter free cash flow totaled approximately $8.6 million, with roughly $70 million in available liquidity supporting further acquisitions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Strata Critical Medical Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.